MedTrace Logo

Stem Cell Study for Patients With Heart Disease

NCT00221182 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2011-06-22

No results posted yet for this study

Summary

The purpose of this study is to determine if stem cell therapy with your own cells (autologous cells) delivered with a catheter to regions of the heart with poor blood flow will be safe and if it will relieve your chest pain, increase the blood flow, and/or improve the cardiac contractility (function) by regenerating blood vessels in your heart.

Conditions

Interventions

GENETIC

Autologous peripheral blood CD34 positive cell therapy

Sponsors & Collaborators

  • Institute of Biomedical Research and Innovation, Kobe, Hyogo, Japan

    collaborator OTHER

  • Kobe City General Hospital

    collaborator OTHER

  • Okayama University School of Medicine

    collaborator UNKNOWN

  • Foundation for Biomedical Research and Innovation

    lead OTHER

Principal Investigators

  • Takayuki Asahara, M.D. · Foundation for Biomedical Research and Innovation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00221182 on ClinicalTrials.gov